EUCTR2005-002538-37-GB进行中（未招募）1 期
Randomised, double-blind study to demonstrate therapeutic equivalence of formoterol fumarate 12µg capsules delivered by Cyclohaler with Foradil in mild to moderate reversible obstructive airways disease.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Clinical diagnosis of mild to moderate reversible obstructive airways disease, with exclusion of other significant pulmonary diseases
- •2. No significant cardiac, other pulmonary, gastrointestinal, hepatic, renal, haematological, uncontrolled diabetes mellitus, neurological and psychiatric disease as determined by medical history, physical examination, biochemical and haematological investigation.
- •3.Male or female subjects between the ages of 18-65 years inclusive.
- •4.Baseline FEV1 greater than or equal to 40% of predicted value, based on ECCS standards using the ethnic corrections where appropriate after withholding short-acting beta-2 agonists for 6 hours and long-acting beta-2 agonists for 24 hours
- •5.Reversibility of FEV1 to 400µg salbutamol by inhalation of at least 15% and 200 mL
- •6.Subjects on either no inhaled steroids or on a stable dose of inhaled steroids (stable for a minimum of 6 weeks prior to study entry).
- •7.Female subjects of child bearing potential must test negative on standard serum pregnancy test and must be willing to practice abstinence or appropriate double barrier contraceptive methods for the duration of the study
- •8.Smoking history of less than 20 pack years; subjects must not have smoked for one month prior to entry onto the study.
- •9.Written informed consent and willingness to comply with protocol procedures, including being willing and able to omit any current inhaled steroid treatment for the morning of dosing days.
- •10.Refrain from strenuous exercise 8 hours before and during each visit
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.History or present evidence of disease, which in the opinion of the Investigator, may affect the subject’s participation in the study or outcome measures.
- •2.Known pregnancy or lactation.
- •3.Known hypersensitivity to salbutamol, formoterol or lactose.
- •4.Involvement in another clinical study with a new chemical entity within the previous four weeks prior to screening.
- •5.Acute lower respiratory infection within four weeks prior to screening.
- •6.Inability to stop any of the prohibited medication, including oral steroids, and subjects on long-acting bronchodilators who are unable to use alternate treatment.
- •7.Subject on unstable dose of inhaled steroids (not on a stable dose for six weeks prior to entry into the study).
- •8.Known history of substance/alcohol abuse.
- •9.Positive test for hepatitis B or hepatitis C.
研究者
相似试验
尚未招募
不适用
A study to measure markers in the breath of patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseACTRN12614000617662ung Institute of Western Australia200
进行中（未招募）
1 期
Effect of testosterone in male patients on regular hemodialysisHypogonadal males undergoing hemodialysis (HD).EUCTR2011-005439-20-SEDept of Renal medicine40
进行中（未招募）
1 期
ASC-201 Plus Trifluridine/Tipiracil for the Treatment of Advanced Gastric CancerAdvanced Gastric Cancer.MedDRA version: 20.0Level: SOCClassification code 10017947Term: Gastrointestinal disordersSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-003799-15-ESAscelia Pharma AB139
已完成
不适用
Greeva basti in viswachiCTRI/2021/04/032654shri Dharamasthala Manjunatheshwara college of ayurveda and hospital30
已完成
不适用
Effect of gamma oryzanol on immunity in healthy volunteersCTRI/2021/03/031920AP Organics Limited30